到 2030 年 CAR-T 细胞疗法的市场预测：按药物类型、目标抗原、应用、最终用户和地区进行全球分析

根据 Stratistics MRC 的数据，2023 年全球 CAR-T 细胞治疗市场规模为 33 亿美元，预计预测期内复合年增长率为 30.5%，到 2030 年将达到 218 亿美元。

CAR-T细胞疗法是嵌合体受体T细胞疗法的缩写，是用于治疗某些类型癌症的突破性免疫疗法。患者自身的 T 细胞（一种免疫细胞）经过基因改造，可在其表面表达嵌合体抗原受体 (CAR)。这个过程通常首先从患者的血液中采集 T 细胞，这个过程称为白血球分离术。然后，这些 T 细胞在实验室中经过基因改造，在其表面表达称为 CAR 的特定受体。这些受体旨在识别并结合通常存在于癌细胞表面的特定蛋白质。

根据世界癌症研究基金会发表的癌症资料，2020年将新增白血病病例474,519例、多发性骨髓瘤病例176,404例、淋巴瘤病例627,439例。

癌症盛行率增加

儘管 CAR-T 技术取得了令人鼓舞的进展，但癌症发生率的增加带来了重大挑战。人口老化、环境因素和生活方式的改变等因素促成了这一趋势。随着对有效癌症治疗的需求不断增加，解决这一不断上升的盛行率已成为 CAR-T 疗法领域的医疗保健提供者和研究人员的当务之急。因此，市场正经历着癌症患者不断增加的令人担忧的趋势。

核准的治疗方法数量有限

在快速发展的 CAR-T 细胞治疗领域，核准的治疗方法有限。这些治疗方法对某些类型的血癌（包括白血病和淋巴瘤）显示出显着疗效。然而，由于高成本、製造流程复杂以及需要进一步研究以扩大适应症和改善安全性，市场仍相对受到限制。

技术进步

CAR-T 细胞疗法的进步正在彻底改变癌症治疗并提供个人化免疫疗法解决方案。增强的製造技术，例如借用的病毒载体设计和自动化细胞处理系统，可简化生产、提高可扩展性并降低成本。 CAR 构建体的标靶修饰可提高肿瘤特异性、减少脱靶效应并增强治疗效果。

製造成本高

CAR-T 细胞市场面临巨大的製造成本，这主要是由于製程复杂且集中。製造 CAR-T 细胞需要先进的细胞工程技术、广泛的品管措施和专门的基础设施。此外，治疗的个人化性质也增加了成本，因为每种治疗都是针对个别患者量身定制的。这些高昂的成本对 CAR-T 细胞疗法的普及和可及性构成了挑战，限制了其在更广泛的患者群体中的使用。

COVID-19 的影响：

COVID-19 的爆发对 CAR-T 细胞治疗市场产生了重大影响，扰乱了临床试验、生产和患者的使用。供应链中断和医院容量减少正在推迟治疗并阻碍市场成长。此外，资源转移和 COVID-19 治疗的优先顺序正在转移人们对 CAR-T 疗法开发和部署的注意力。儘管面临挑战，但从长远来看，对免疫疗法和创新疗法的更多关注可能会推动市场復苏和成长。

Tisagenleucel 业务预计将在预测期内成为最大的业务

Tissagenleucel 业务预计将成为预测期内最大的业务。这种药物旨在针对特定癌细胞，在某些类型的白血病和淋巴瘤患者中显示出显着的疗效。它的核准标誌着免疫治疗的一个重要里程碑，为已经用尽常规治疗方法的患者带来了新的希望。这项成功很快就使 Tisagenlecleucel 成为 CAR-T 细胞治疗市场的中流砥柱，推动了该领域的进步和进一步研究。

预计淋巴瘤细分市场在预测期内复合年增长率最高

由于免疫疗法的进步，预计淋巴瘤领域在预测期内将出现最高的复合年增长率。 CAR T 细胞疗法修改患者自身的免疫细胞，以便更好地识别和攻击癌细胞。这种个人化方法在各种淋巴瘤亚型中显示出有希望的结果，特别是对传统治疗没有反应的患者。由于正在进行的研究和临床试验，淋巴瘤治疗市场预计将进一步成长。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。 CAR-T疗法专注于个人化医疗，在白血病和淋巴瘤等多种癌症的治疗中越来越受欢迎。该地区强大的医疗基础设施，加上支持性的法律规范，正在促进市场扩张。此外，製药公司和学术机构之间的合作正在加速这一前景广阔的领域的创新，预示着光明的市场前景。

复合年增长率最高的地区：

预计亚太地区在预测期内复合年增长率最高。每个国家的癌症盛行率不断上升，再加上人们所认识的提高和诊断技术的改进，正在扩大可能受益于 CAR T 细胞疗法的患者数量。各国正在进行的CAR-T细胞治疗临床试验数量也大幅增加。这些临床试验正在评估不同 CAR-T 疗法在不同类型癌症中的安全性和有效性，有助于该地区该领域的进展。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

• 公司简介
  • 其他市场参与者的综合分析（最多 3 家公司）
  • 主要企业SWOT分析（最多3家企业）
• 区域分割
  • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
• 竞争基准化分析
  • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

• 概述
• 相关利益者
• 调查范围
• 调查方法
  • 资料探勘
  • 资料分析
  • 资料检验
  • 研究途径
• 调查来源
  • 主要调查来源
  • 二次调查来源
  • 先决条件

第三章市场趋势分析

• 促进因素
• 抑制因素
• 机会
• 威胁
• 应用分析
• 最终用户分析
• 新兴市场
• 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

• 供应商的议价能力
• 买方议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第五章全球CAR-T细胞治疗市场：依药物类型

• 布雷克斯卡布塔基因au​​toleucel
• 阿克斯卡塔基因纤毛
• 蒂萨让勒克鲁塞尔
• 其他类型的药物

第六章全球CAR-T细胞治疗市场：依目标抗原

• CD19
• B细胞成熟抗原（BCMA）
• GD2
• CD20
• 其他标靶抗原

第七章全球 CAR-T 细胞治疗市场：依应用分类

• 急性淋巴性白血病
• 淋巴瘤
• 慢性淋巴性白血病
• 滤泡性淋巴瘤
• 肝细胞癌
• 大肠直肠癌
• 其他用途

第八章全球 CAR-T 细胞治疗市场：依最终使用者分类

• 癌症治疗中心
• 医院
• 其他最终用户

第九章全球CAR-T细胞治疗市场：依地区

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙
  • 其他欧洲国家
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 纽西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 卡达
  • 南非
  • 其他中东和非洲

第10章 主要进展

• 合约、伙伴关係、协作和合资企业
• 收购和合併
• 新产品发布
• 业务扩展
• 其他关键策略

第十一章 公司简介

• Gilead Sciences Inc.
• Bristol-Myers Squibb
• Novartis AG
• Cartesian Therapeutics Inc.
• Merck & Co. Inc.
• Intellia Therapeutics
• Juno Therapeutics Inc.
• Bluebird Bio Inc.
• Sorrento Therapeutics Inc.
• Autolus Therapeutics
• Caribou Biosciences Inc.
• Miltenyi Biotech
• Celgene Corporation
• Aurora Biopharma Inc.
• Pfizer, Inc.

According to Stratistics MRC, the Global CAR-T Cell Therapy Market is accounted for $3.3 billion in 2023 and is expected to reach $21.8 billion by 2030 growing at a CAGR of 30.5% during the forecast period. CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a groundbreaking form of immunotherapy used in the treatment of certain types of cancer. It involves genetically modifying a patient's own T cells (a type of immune cell) to express chimeric antigen receptors (CARs) on their surface. The process typically starts by collecting T cells from the patient's blood through a process called leukapheresis. These T cells are then genetically engineered in a laboratory to express specific receptors called CARs on their surface. These receptors are designed to recognize and bind to specific proteins, typically found on the surface of cancer cells.

According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Despite the promising advancements in CAR-T technology, the rise in cancer incidence poses significant challenges. Factors such as aging populations, environmental factors, and lifestyle changes contribute to this trend. As the demand for effective cancer treatments grows, addressing this rising prevalence becomes imperative for healthcare providers and researchers in the field of CAR-T therapy. Thus, the market is experiencing a concerning trend with an increasing prevalence of cancer cases.

Restraint:

Limited number of approved therapies

In the rapidly evolving field of CAR-T cell therapy, only a limited number of treatments have gained approval. These therapies have shown remarkable efficacy in treating certain types of blood cancers, including leukemia and lymphoma. However, the market remains relatively constrained due to high costs, complex manufacturing processes, and the need for further research to expand indications and improve safety profiles.

Opportunity:

Advancements in technology

Advancements in CAR-T cell therapy have revolutionized cancer treatment, offering personalized immunotherapy solutions. Enhanced manufacturing techniques, such as lent viral vector design and automated cell processing systems, streamline production, improving scalability and reducing costs. Targeted modifications to CAR constructs enhance tumour specificity and reduce off-target effects, boosting therapeutic efficacy.

Threat:

High manufacturing costs

The market faces significant manufacturing costs, primarily due to the complex and labor-intensive process involved. Manufacturing CAR-T cells requires sophisticated cell engineering techniques, extensive quality control measures, and specialized infrastructure. Additionally, personalized nature of the therapy adds to the expenses, as each treatment is tailored to individual patients. These high costs pose challenges for widespread adoption and accessibility of CAR-T cell therapy, limiting its availability to a broader patient population.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the CAR-T cell therapy market, causing disruptions in clinical trials, manufacturing, and patient access. Supply chain disruptions and reduced hospital capacity have delayed treatments and hindered market growth. Additionally, diverted resources and prioritization of COVID-19 care have diverted attention from CAR-T therapy development and deployment. Despite challenges, increased focus on immunotherapy and innovative treatments may drive market recovery and growth in the long term.

The tisagenlecleucel segment is expected to be the largest during the forecast period

The tisagenlecleucel segment is expected to be the largest during the forecast period. Engineered to target specific cancer cells, it has shown remarkable efficacy in patients with certain types of leukemia and lymphoma. Its approval marked a significant milestone in immunotherapy, offering new hope for patients who have exhausted conventional treatments. With its success, Tisagenlecleucel has quickly become a pivotal player in the CAR-T cell therapy market, driving advancements and further research in the field.

The lymphoma segment is expected to have the highest CAGR during the forecast period

The lymphoma segment is expected to have the highest CAGR during the forecast period driven by advancements in immunotherapy. CAR-T cell therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. This personalized approach has shown promising results in various lymphoma subtypes, particularly in patients who have not responded to conventional treatments. With ongoing research and clinical trials, the market for therapy in lymphoma is poised for further growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. With a focus on personalized medicine, CAR-T therapies are gaining traction for treating various types of cancers, including leukemia and lymphoma. The region's robust healthcare infrastructure, coupled with supportive regulatory frameworks, fosters market expansion. Moreover, collaborations between pharmaceutical companies and academic institutions contribute to accelerating innovation in this promising field, promising a bright outlook for the market.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The rising prevalence of cancer in countries, coupled with growing awareness and improved diagnosis, was creating a larger pool of patients who could potentially benefit from CAR-T cell therapy. There was a significant increase in the number of clinical trials for CAR-T cell therapies being conducted in countries. These trials were evaluating the safety and efficacy of various CAR-T treatments across different types of cancer, contributing to the advancement of the field in the region.

Key players in the market

Some of the key players in CAR-T Cell Therapy market include Gilead Sciences Inc., Bristol-Myers Squibb, Novartis AG, Cartesian Therapeutics Inc., Merck & Co. Inc., Intellia Therapeutics, Juno Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics Inc., Autolus Therapeutics, Caribou Biosciences Inc., Miltenyi Biotech, Celgene Corporation, Aurora Biopharma Inc. and Pfizer, Inc.

Key Developments:

In December 2023, Bristol-Myers Squibb announced that it received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

In May 2023, Autolus Therapeutics plc announced that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress.

Drug Types Covered:

• Brexucabtagene Autoleucel
• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Other Drug Types

Target Antigens Covered:

• CD19
• B-Cell Maturation Antigen (BCMA)
• GD2
• CD20
• Other Target Antigens

Applications Covered:

• Acute Lymphocytic Leukemia
• Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hepatocellular Carcinoma
• Colorectal Cancer
• Other Applications

End Users Covered:

• Cancer Treatment Centers
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global CAR T-Cell Therapy Market, By Drug Type

• 5.1 Introduction
• 5.2 Brexucabtagene Autoleucel
• 5.3 Axicabtagene Ciloleucel
• 5.4 Tisagenlecleucel
• 5.5 Other Drug Types

6 Global CAR T-Cell Therapy Market, By Target Antigen

• 6.1 Introduction
• 6.2 CD19
• 6.3 B-Cell Maturation Antigen (BCMA)
• 6.4 GD2
• 6.5 CD20
• 6.6 Other Target Antigens

7 Global CAR T-Cell Therapy Market, By Application

• 7.1 Introduction
• 7.2 Acute Lymphocytic Leukemia
• 7.3 Lymphoma
• 7.4 Chronic Lymphocytic Leukemia
• 7.5 Follicular Lymphoma
• 7.6 Hepatocellular Carcinoma
• 7.7 Colorectal Cancer
• 7.8 Other Applications

8 Global CAR T-Cell Therapy Market, By End User

• 8.1 Introduction
• 8.2 Cancer Treatment Centers
• 8.3 Hospitals
• 8.4 Other End Users

9 Global CAR T-Cell Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Gilead Sciences Inc.
• 11.2 Bristol-Myers Squibb
• 11.3 Novartis AG
• 11.4 Cartesian Therapeutics Inc.
• 11.5 Merck & Co. Inc.
• 11.6 Intellia Therapeutics
• 11.7 Juno Therapeutics Inc.
• 11.8 Bluebird Bio Inc.
• 11.9 Sorrento Therapeutics Inc.
• 11.10 Autolus Therapeutics
• 11.11 Caribou Biosciences Inc.
• 11.12 Miltenyi Biotech
• 11.13 Celgene Corporation
• 11.14 Aurora Biopharma Inc.
• 11.15 Pfizer, Inc.

List of Tables

• Table 1 Global CAR T-Cell Therapy Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 4 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 5 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 6 Global CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 7 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 8 Global CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 9 Global CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 11 Global CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 12 Global CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 13 Global CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 14 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 15 Global CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 16 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 17 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 18 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 19 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 20 Global CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 21 Global CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 22 Global CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 23 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 24 Global CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 25 North America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 26 North America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 27 North America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 28 North America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 29 North America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 30 North America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 31 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 32 North America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 33 North America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 34 North America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 35 North America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 36 North America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 37 North America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 38 North America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 39 North America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 40 North America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 41 North America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 42 North America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 43 North America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 44 North America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 45 North America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 46 North America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 47 North America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 48 North America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 49 Europe CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 50 Europe CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 51 Europe CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 52 Europe CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 53 Europe CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 54 Europe CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 55 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 56 Europe CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 57 Europe CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 58 Europe CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 59 Europe CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 60 Europe CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 61 Europe CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 62 Europe CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 63 Europe CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 64 Europe CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 65 Europe CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 66 Europe CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 67 Europe CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 68 Europe CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 69 Europe CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 70 Europe CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 71 Europe CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 72 Europe CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 73 Asia Pacific CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 74 Asia Pacific CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 75 Asia Pacific CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 76 Asia Pacific CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 77 Asia Pacific CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 78 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 79 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 80 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 81 Asia Pacific CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 82 Asia Pacific CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 83 Asia Pacific CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 84 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 85 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 86 Asia Pacific CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 87 Asia Pacific CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 88 Asia Pacific CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 89 Asia Pacific CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 90 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 91 Asia Pacific CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 92 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 93 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 94 Asia Pacific CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 95 Asia Pacific CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 96 Asia Pacific CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 97 South America CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 98 South America CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 99 South America CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 100 South America CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 101 South America CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 102 South America CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 103 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 104 South America CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 105 South America CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 106 South America CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 107 South America CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 108 South America CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 109 South America CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 110 South America CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 111 South America CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 112 South America CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 113 South America CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 114 South America CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 115 South America CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 116 South America CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 117 South America CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 118 South America CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 119 South America CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 120 South America CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 121 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Country (2021-2030) ($MN)
• Table 122 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 123 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Brexucabtagene Autoleucel (2021-2030) ($MN)
• Table 124 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (2021-2030) ($MN)
• Table 125 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (2021-2030) ($MN)
• Table 126 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 127 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2021-2030) ($MN)
• Table 128 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD19 (2021-2030) ($MN)
• Table 129 Middle East & Africa CAR T-Cell Therapy Market Outlook, By B-Cell Maturation Antigen (BCMA) (2021-2030) ($MN)
• Table 130 Middle East & Africa CAR T-Cell Therapy Market Outlook, By GD2 (2021-2030) ($MN)
• Table 131 Middle East & Africa CAR T-Cell Therapy Market Outlook, By CD20 (2021-2030) ($MN)
• Table 132 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Target Antigens (2021-2030) ($MN)
• Table 133 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2021-2030) ($MN)
• Table 134 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Acute Lymphocytic Leukemia (2021-2030) ($MN)
• Table 135 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 136 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2021-2030) ($MN)
• Table 137 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2021-2030) ($MN)
• Table 138 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
• Table 139 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 140 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 141 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2021-2030) ($MN)
• Table 142 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
• Table 143 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 144 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Other End Users (2021-2030) ($MN)